Search
Ukraine Bridge Funding - information for applicants
The EHA Ukraine Bridge Funding Program is a 1-year non-clinical funding opportunity for Ukrainian hematologists and researchers in hematology (see press release here), now in collaboration with the American Society of Hematology, which will participate in funding and the selection…
Read moreHighlights of Past EHA (HOPE) Latin America (LA) 2023 - report
October 26, 2023 – São Paulo, Brazil
Meeting chairs:
A Almeida - President EHA
JF Comenalli Marques Jr - President ABHH
C Chiattone - President HEMO 2023
This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…
Connecting experts on inherited anemias and iron defects in Budapest
October 12-14, 2023 – Budapest, Hungary
Meeting Chairs:
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon
Achille Iolascon, University Federico II of Naples, Naples, Italy
In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…
Abstract submission & Awards
Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.
Read moreNurses abstract submission
Abstract and Case Report submission for nurses is now closed. Nurses abstract submissionDon’t miss out on a great opportunity to submit an abstract for the 6th EHA-EBMT European CAR T-cell Meeting 2024.
Read moreEHA-LSHBT Virtual Hematology Updates
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.
Read moreCommonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML
November 2-4 - Budapest, Hungary
Meeting Chairs:
Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- »